Activity of the ß-Lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D ß-Lactamases from acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Vázquez Ucha, Juan Carlos ^a   Maneiro, María ^b   Martínez Guitián, Marta ^a   Buynak, John ^c   Bethel, Christopher R ^d   Bonomo, Robert A ^d,e   Bou, Germán ^a   Poza, Margarita ^a   González Bello, Concepción ^b   Beceiro, Alejandro ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b s n   (Spain)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Acinetobacter baumannii; Antimicrobial resistance; Carbapenem hydrolyzing class D lactamases; lactamase inhibitors

Indexed keywords

AMPICILLIN; AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEMASE; CLASS D CARBAPENEMASE; IMIPENEM; LN 1 255; MEROPENEM; NITROCEFIN; TAZOBACTAM; UNCLASSIFIED DRUG; AZABICYCLO DERIVATIVE; BETA-LACTAMASE OXA-24; BETA-LACTAMASE OXA-51, ACINETOBACTER BAUMANNII; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; LN 1-255; PENICILLANIC ACID; PENICILLIN DERIVATIVE; SULFOXIDE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROLYSIS KINETICS; INHIBITION KINETICS; KINETIC PARAMETERS; KINETICS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; HUMAN; HYDROLYSIS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEMS; CATALYTIC DOMAIN; CEPHALOSPORINS; CYCLIC S-OXIDES; HUMANS; HYDROLYSIS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; PENICILLANIC ACID; PENICILLINS;

EID: 85028846513     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01172-17     Document Type: Article

References (69)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582. https://doi.org/10.1128/CMR.00058-07.
2. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5:939–951. https://doi.org/10.1038/nrmicro1789.
3. Kallen AJ, Hidron AI, Patel J, Srinivasan A. 2010. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 31:528–531. https://doi.org/10.1086/ 652152.
4. Rosenthal VD, Maki DG, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, Leblebicioglu H, Abu Khader I, Miranda Novales MG, Berba R, Ramírez Wong FM, Barkat A, Pino OR, Dueñas L, Mitrev Z, Bijie H, Gurskis V, Kanj SS, Mapp T, Hidalgo RF, Ben Jaballah N, Raka L, Gikas A, Ahmed A, Thu TA, Guzmán Siritt ME, INICC Members. 2010. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 38:95–104.e2. https://doi.org/10.1016/j.ajic.2009.12.004.
5. Toth M, Antunes NT, Stewart NK, Frase H, Bhattacharya M, Smith CA, Vakulenko SB. 2016. Class D ß-lactamases do exist in Gram-positive bacteria. Nat Chem Biol 12:9–14. https://doi.org/10.1038/nchembio.1950.
6. Poole K. 2004. Resistance to beta-lactam antibiotics. Cell Mol Life Sci 61:2200–2223. https://doi.org/10.1007/s00018-004-4060-9.
7. Massova I, Mobashery S. 1998. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother 42:1–17. https://doi.org/10.1093/jac/42.1.1.
8. Kaitany KC, Klinger NV, June CM, Ramey ME, Bonomo RA, Powers RA, Leonard DA. 2013. Structures of the class D carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam. Antimicrob Agents Chemother 57:4848–4855. https://doi.org/10.1128/AAC.00762-13.
9. Paton R, Miles RS, Hood J, Amyes SG. 1993. ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2:81– 87. https://doi.org/10.1016/0924-8579(93)90045-7.
10. Leonard DA, Bonomo RA, Powers RA. 2013. Class D ß-lactamases: a reappraisal after five decades. Acc Chem Res 46:2407–2415. https://doi.org/10.1021/ar300327a.
11. Afzal-Shah M, Woodford N, Livermore DM. 2001. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 45:583–588. https://doi.org/10.1128/AAC.45.2.583-588.2001.
12. Bou G, Oliver A, Martínez-Beltrán J. 2000. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 44:1556–1561. https://doi.org/10.1128/AAC.44.6.1556-1561.2000.
13. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. 2007. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother 51:1530–1533. https://doi.org/10.1128/AAC.01132-06.
14. Poirel L, Marqué S, Héritier C, Segonds C, Chabanon G, Nordmann P. 2005. OXA-58, a novel class D ß-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 49:202–208. https://doi.org/10.1128/AAC.49.1.202-208.2005.
15. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. 2009. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 53:5035–5038. https://doi.org/10.1128/AAC.00856-09.
16. Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G, Seifert H. 2013. OXA-235, a novel class D ß-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 57:2121–2126. https://doi.org/10.1128/AAC.02413-12.
17. Poirel L, Naas T, Nordmann P. 2010. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother 54:24–38. https://doi.org/10.1128/AAC.01512-08.
18. Evans BA, Amyes SG. 2014. OXA -lactamases. Clin Microbiol Rev 27: 241–263. https://doi.org/10.1128/CMR.00117-13.
19. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–458. https://doi.org/10.1128/CMR.00001-07.
20. Walther-Rasmussen J, Hoiby N. 2006. OXA-type carbapenemases. J Antimicrob Chemother 57:373–383. https://doi.org/10.1093/jac/dki482.
21. Mugnier PD, Poirel L, Naas T, Nordmann P. 2010. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 16:35– 40. https://doi.org/10.3201/eid1601.090852.
22. Smith CA, Antunes NT, Stewart NK, Frase H, Toth M, Kantardjieff KA, Vakulenko S. 2015. Structural basis for enhancement of carbapenemase activity in the OXA-51 family of class D ß-lactamases. ACS Chem Biol 10:1791–1796. https://doi.org/10.1021/acschembio.5b00090.
23. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. 2007. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 26:793– 800. https://doi.org/10 .1007/s10096-007-0371-8.
24. Livermore DM, Hill RL, Thomson H, Charlett A, Turton JF, Pike R, Patel BC, Manuel R, Gillespie S, Balakrishnan I, Barrett SP, Cumberland N, Twagira M, C-MRAB Study Group. 2010. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents 35:19 –24. https://doi.org/10.1016/j.ijantimicag.2009.09.014.
25. Rhomberg PR, Jones RN. 2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 65:414–426. https://doi.org/10.1016/j.diagmicrobio.2009.08.020.
26. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160–201. https://doi.org/10.1128/CMR.00037-09.
27. Bush K, Jacoby GA. 2010. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 54:969–976. https://doi.org/10.1128/AAC.01009-09.
28. Lahiri SD, Mangani S, Jahic H, Benvenuti M, Durand-Reville TF, De Luca F, Ehmann DE, Rossolini GM, Alm RA, Docquier JD. 2015. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48. ACS Chem Biol 10:591–600. https://doi.org/10.1021/cb500703p.
29. Perez-Llarena FJ, Bou G. 2009. Beta-lactamase inhibitors: the story so far. Curr Med Chem 16:3740 –3765. https://doi.org/10.2174/092986709789104957.
30. Buynak JD, Rao AS, Doppalapudi VR, Adam G, Petersen PJ, Nidamarthy SD. 1999. The synthesis and evaluation of 6-alkylidene-2=beta-substituted pe-nam sulfones as beta-lactamase inhibitors. Bioorg Med Chem Lett 9:1997–2002. https://doi.org/10.1016/S0960-894X(99)00325-X.
31. Pattanaik P, Bethel CR, Hujer AM, Hujer KM, Distler AM, Taracila M, Anderson VE, Fritsche TR, Jones RN, Pagadala SR, van den Akker F, Buynak JD, Bonomo RA. 2009. Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2=-substituted penicillin sulfone. J Biol Chem 284:945–953. https://doi.org/10.1074/jbc.M806833200.
32. Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA. 2010. Penicillin sulfone inhibitors of class D beta-lactamases. Antimicrob Agents Chemother 54:1414 –1424. https://doi.org/10.1128/AAC.00743-09.
33. Vallejo JA, Martínez-Guitián M, Vázquez-Ucha JC, González-Bello C, Poza M, Buynak JD, Bethel CR, Bonomo RA, Bou G, Beceiro A. 2016. LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48. J Antimicrob Chemother 71:2171–2180. https://doi.org/10.1093/jac/dkw105.
34. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. http://www.eucast.org/clinical_breakpoints.
35. Bou G, Santillana E, Sheri A, Beceiro A, Sampson JM, Kalp M, Bethel CR, Distler AM, Drawz SM, Pagadala SR, van den Akker F, Bonomo RA, Romero A, Buynak JD. 2010. Design, synthesis, and crystal structures of 6-alkylidene-2=-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J Am Chem Soc 132:13320 –13331. https://doi.org/10.1021/ja104092z.
36. Torol S, Kasap M. 2013. Purification and characterization of OXA-23 from Acinetobacter baumannii. J Enzyme Inhib Med Chem 28:836–842. https://doi.org/10.3109/14756366.2012.689296.
37. Verma V, Testero SA, Amini K, Wei W, Liu J, Balachandran N, Monoharan T, Stynes S, Kotra LP, Golemi-Kotra D. 2011. Hydrolytic mechanism of OXA-58 enzyme, a carbapenem-hydrolyzing class D ß-lactamase from Acinetobacter baumannii. J Biol Chem 286:37292–37303. https://doi.org/10.1074/jbc.M111.280115.
38. Smith CA, Antunes NT, Stewart NK, Toth M, Kumarasiri M, Chang M, Mobashery S, Vakulenko SB. 2013. Structural basis for carbapenemase activity of the OXA-23 -lactamase from Acinetobacter baumannii. Chem Biol 20:1107–1115. https://doi.org/10.1016/j.chembiol.2013.07.015.
39. Pratap S, Katiki M, Gill P, Kumar P, Golemi-Kotra D. 2015. Active-site plasticity is essential to carbapenem hydrolysis by OXA-58 class D ß-lactamase of Acinetobacter baumannii. Antimicrob Agents Chemother 60:75– 86. https://doi.org/10.1128/AAC.01393-15.
40. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Gallo Cassarino T, Bertoni M, Bordoli L, Schwede T. 2014. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42:W252–W258. https://doi.org/ 10.1093/nar/gku340.
41. June CM, Muckenthaler TJ, Schroder EC, Klamer ZL, Wawrzak Z, Powers RA, Szarecka A, Leonard DA. 2016. The structure of a doripenem-bound OXA-51 class D ß-lactamase variant with enhanced carbapenemase activity. Protein Sci 25:2152–2163. https://doi.org/10.1002/pro.3040.
42. Saino H, Sugiyabu T, Ueno G, Yamamoto M, Ishii Y, Miyano M. 2015. Crystal structure of OXA-58 with the substrate-binding cleft in a closed state: insights into the mobility and stability of the OXA-58 structure. PLoS One 10:e0145869. https://doi.org/10.1371/journal.pone.0145869.
43. Santillana E, Beceiro A, Bou G, Romero A. 2007. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci U S A 104:5354–5359. https://doi.org/10.1073/pnas.0607557104.
44. Schneider KD, Ortega CJ, Renck NA, Bonomo RA, Powers RA, Leonard DA. 2011. Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem. J Mol Biol 406: 583–594. https://doi.org/10.1016/j.jmb.2010.12.042.
45. Soto E, Shoji S, Muto C, Tomono Y, Marshall S. 2014. Population phar-macokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol 77:509–521. https://doi.org/10.1111/bcp.12232.
46. Das S, Li J, Armstrong J, Learoyd M, Edeki T. 2015. Randomized phar-macokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect 3:e00172. https://doi.org/10.1002/prp2.172.
47. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D ß-lactamases. J Biol Chem 288:27960–27971. https://doi.org/10.1074/jbc.M113.485979.
48. Bethel CR, Distler AM, Ruszczycky MW, Carey MP, Carey PR, Hujer AM, Taracila M, Helfand MS, Thomson JM, Kalp M, Anderson VE, Leonard DA, Hujer KM, Abe T, Venkatesan AM, Mansour TS, Bonomo RA. 2008. Inhibition of OXA-1 beta-lactamase by penems. Antimicrob Agents Chemother 52:3135–3143. https://doi.org/10.1128/AAC.01677-07.
49. Che T, Bethel CR, Pusztai-Carey M, Bonomo RA, Carey PR. 2014. The different inhibition mechanisms of OXA-1 and OXA-24 -lactamases are determined by the stability of active site carboxylated lysine. J Biol Chem 289:6152– 6164. https://doi.org/10.1074/jbc.M113.533562.
50. Weiss WJ, Petersen PJ, Murphy TM, Tardio L, Yang Y, Bradford PA, Venkatesan AM, Abe T, Isoda T, Mihira A, Ushirogochi H, Takasake T, Projan S, O’Connell J, Mansour TS. 2004. In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors. Antimicrob Agents Chemother 48:4589–4596. https://doi.org/10.1128/AAC.48.12.4589-4596.2004.
51. Adediran SA, Nukaga M, Baurin S, Frère JM, Pratt RF. 2005. Inhibition of class D beta-lactamases by acyl phosphates and phosphonates. Antimicrob Agents Chemother 49:4410–4412. https://doi.org/10.1128/AAC.49.10.4410-4412.2005.
52. Majumdar S, Adediran SA, Nukaga M, Pratt RF. 2005. Inhibition of class D beta-lactamases by diaroyl phosphates. Biochemistry 44:16121–16129. https://doi.org/10.1021/bi051719s.
53. Tan Q, Ogawa AM, Raghoobar SL, Wisniewski D, Colwell L, Park YW, Young K, Hermes JD, Dininno FP, Hammond ML. 2011. Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Bioorg Med Chem Lett 21:4363– 4365. https://doi.org/10.1016/j.bmcl.2011.04.122.
54. Tan Q, Ogawa AM, Painter RE, Park YW, Young K, DiNinno FP. 2010. 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity. Bioorg Med Chem Lett 20:2622–2624. https://doi.org/10.1016/j.bmcl.2010.02.065.
55. Nichols DA, Renslo AR, Chen Y. 2014. Fragment-based inhibitor discovery against -lactamase. Future Med Chem 6:413–427. https://doi.org/10.4155/fmc.14.10.
56. Beck J, Vercheval L, Bebrone C, Herteg-Fernea A, Lassaux P, Marchand-Brynaert J. 2009. Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and ho-mologs of citrate and isocitrate. Bioorg Med Chem Lett 19:3593–3597. https://doi.org/10.1016/j.bmcl.2009.04.149.
57. Docquier JD, Benvenuti M, Calderone V, Giuliani F, Kapetis D, De Luca F, Rossolini GM, Mangani S. 2010. Crystal structure of the narrow-spectrum OXA-46 class D beta-lactamase: relationship between active-site lysine carbamylation and inhibition by polycarboxylates. Antimicrob Agents Chemother 54:2167–2174. https://doi.org/10.1128/AAC.01517-09.
58. Buynak JD. 2004. The discovery and development of modified penicillin- and cephalosporin-derived beta-lactamase inhibitors. Curr Med Chem 11:1951–1964. https://doi.org/10.2174/0929867043364847.
59. Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J. 2007. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologi-cally related and unrelated Acinetobacter baumannii clinical isolates in Spain. Clin Microbiol Infect 13:1192–1198. https://doi.org/10.1111/j.1469-0691.2007.01825.x.
60. Merino M, Poza M, Roca I, Barba MJ, Sousa MD, Vila J, Bou G. 2014. Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain. Microb Drug Resist 20: 259–263. https://doi.org/10.1089/mdr.2013.0127.
61. Aranda J, Poza M, Pardo BG, Rumbo S, Rumbo C, Parreira JR, Rodríguez-Velo P, Bou G. 2010. A rapid and simple method for constructing stable mutants of Acinetobacter baumannii. BMC Microbiol 10:279. https://doi.org/10.1186/1471-2180-10-279.
62. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 17th informational supplement M07–A9. Clinical and Laboratory Standards Institute, Wayne, PA.
63. Hsieh MH, Yu CM, Yu VL, Chow JW. 1993. Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis 16:343–349. https://doi.org/10.1016/0732-8893(93)90087-N.
64. Golemi D, Maveyraud L, Vakulenko S, Samama JP, Mobashery S. 2001. Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases. Proc Natl Acad Sci U S A 98:14280–14285. https://doi.org/10.1073/pnas.241442898.
65. Winkler ML, Papp-Wallace KM, Bonomo RA. 2015. Activity of ceftazidime/ avibactam against isogenic strains of Escherichia coli containing KPC and SHV ß-lactamases with single amino acid substitutions in the -loop. J Antimicrob Chemother 70:2279 –2286. https://doi.org/10.1093/jac/dkv094.
66. Papp-Wallace KM, Winkler ML, Gatta JA, Taracila MA, Chilakala S, Xu Y, Johnson JK, Bonomo RA. 2014. Reclaiming the efficacy of -lactam--lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Antimicrob Agents Chemother 58:4290–4297. https://doi.org/10.1128/AAC.02625-14.
67. Bethel CR, Taracila M, Shyr T, Thomson JM, Distler AM, Hujer KM, Hujer AM, Endimiani A, Papp-Wallace K, Bonnet R, Bonomo RA. 2011. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems. Antimicrob Agents Chemother 55:3465–3475. https://doi.org/10.1128/AAC.00089-11.
68. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Jr, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas ¨O, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ. 2009. Gaussian 09, revision D.01. Gaussian, Inc., Wallingford, CT.
69. DeLano WL. 2008. The PyMOL molecular graphics system. DeLano Scientific LLC, Palo Alto, CA.